Allogene Therapeutics (ALLO) Receivables - Accured (2018 - 2019)

Allogene Therapeutics (ALLO) reported Receivables - Accured of $2.3 million for Q3 2019, down 28.86% sequentially from $3.3 million in Q2 2019.

Allogene Therapeutics (ALLO) Receivables - Accured (2018 - 2019) Analysis & Trends

Allogene Therapeutics (ALLO) has 2 years of Receivables - Accured data on file, last reported at $2.3 million in Q3 2019.

For the quarter ending Q3 2019, Receivables - Accured changed N/A year-over-year to $2.3 million; the trailing twelve-month figure through Sep 2019 stood at $2.3 million (changed N/A YoY), and the FY2018 full-year result was $3.1 million, changed N/A from the prior year.
Receivables - Accured retreated to $2.3 million in Q3 2019, from $3.3 million in the prior quarter.
In the past five years, Receivables - Accured ranged from a high of $3.4 million in Q1 2019 to a low of $2.3 million in Q3 2019.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables - Accured (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	-
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Allogene Therapeutics	437.33 Mn	437.33 Mn	-	-

Download Data